Order Article Reprints

Mayr C, Kiesslich T, Erber S, Bekric D, Dobias H, Beyreis M, Ritter M, Jäger T, Neumayer B, Winkelmann P, et al. HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer. Cancers. 2021; 13(15):3862. https://doi.org/10.3390/cancers13153862

Mayr, Christian, Tobias Kiesslich, Sara Erber, Dino Bekric, Heidemarie Dobias, Marlena Beyreis, Markus Ritter, Tarkan Jäger, Bettina Neumayer, Paul Winkelmann, and et al. 2021. "HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer" Cancers 13, no. 15: 3862. https://doi.org/10.3390/cancers13153862

Mayr, C., Kiesslich, T., Erber, S., Bekric, D., Dobias, H., Beyreis, M., Ritter, M., Jäger, T., Neumayer, B., Winkelmann, P., Klieser, E., & Neureiter, D. (2021). HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer. Cancers, 13(15), 3862. https://doi.org/10.3390/cancers13153862